ProCE Banner Activity

Phase Ib/II Study of Ivosidenib Plus Venetoclax With or Without Azacitidine in Patients With IDH1-Mutated Hematologic Malignancies

Slideset Download
Conference Coverage
Combination of ivosidenib plus venetoclax with or without azacitidine was well tolerated and effective in patients with IDH1-mutated hematologic malignancies.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono